---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-052753"
form_type: "8-K/A"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:37:39.354953+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q3 net loss $14.0M ($0.24/share); chairman exercises warrants for $10M

## Summary
- Net loss $14.0M ($0.24 loss per share) vs $8.6M ($0.14) in Q3 2022; includes $3.6M non-cash deemed dividend from warrant modification.
- Chairman Richard Uihlein exercised 2.24M warrants at $4.49/share, providing $10M cash; market price was $1.81.
- Cash and equivalents $20.4M; additional $30M credit line from chairman; cash sufficient through at least Dec 2024.
- Belapectin safety profile positive; interim analysis for NAVIGATE trial expected Q4 2024.
- Dr. Benjamin Carson Sr. nominated to Board of Directors.

## SEC filing metadata
- accession: 0001140361-23-052753
- form_type: 8-K/A
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/ef20014607_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-052753
- JSON: https://secwatch.observer/filing/0001140361-23-052753.json
- Plain text: https://secwatch.observer/filing/0001140361-23-052753.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported financial results for nine months ended September 30, 2023.
  - Period: nine months ended September 30, 2023
  - Result: reported results
  source text: Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, EPS ($0.24) per share.
  - Period: three months ended September 30, 2023
  - Net income: net loss applicable to common stockholders of $14.0 million
  - EPS: ($0.24) per share
  - Result: reported results
  source text: For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.